Cargando…

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation

Detalles Bibliográficos
Autores principales:	Battipaglia, Giorgia, Saraceni, Francesco, Malard, Florent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978937/ https://www.ncbi.nlm.nih.gov/pubmed/35387115 http://dx.doi.org/10.3389/fonc.2022.863800

Ejemplares similares

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
por: Maffini, Enrico, et al.
Publicado: (2022)

Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria
por: Battipaglia, Giorgia, et al.
Publicado: (2019)

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Antar, Ahmad I., et al.
Publicado: (2020)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

Editorial: The latest advances in transplantation for AML
por: Chiusolo, Patrizia, et al.
Publicado: (2023)

Editorial: Novel mechanisms for the treatment of AML before and after transplant
por: Kasner, Margaret T.
Publicado: (2022)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse
por: Salhotra, Amandeep, et al.
Publicado: (2022)

Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML
por: Metafuni, Elisabetta, et al.
Publicado: (2022)

An Unconventional View of T Cell Reconstitution After Allogeneic Hematopoietic Cell Transplantation
por: Andrlová, Hana, et al.
Publicado: (2021)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Targeting KRAS: The Elephant in the Room of Epithelial Cancers
por: Merz, Valeria, et al.
Publicado: (2021)

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption
por: Morin, Sarah, et al.
Publicado: (2023)

A diffuse rash in a patient after allogeneic hematopoietic stem cell transplant for AML
por: Ferdjallah, Asmaa, et al.
Publicado: (2020)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant
por: Liu, Pengjiang, et al.
Publicado: (2020)

Long-term health outcomes of allogeneic hematopoietic stem cell transplantation
por: Kelkar, Amar H., et al.
Publicado: (2023)

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
por: Teich, Katrin, et al.
Publicado: (2023)

The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Köhler, Natalie, et al.
Publicado: (2021)

Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
por: Godfrey, James, et al.
Publicado: (2022)

Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation
por: Park, Woochan, et al.
Publicado: (2023)

Gastrointestinal Complications after Allogeneic Hematopoietic Stem Cell Transplant: A Multidisciplinary Approach with Early Endoscopic Evaluation
por: Tarantino, Giuseppe, et al.
Publicado: (2021)

Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients
por: Hobbs, Gabriela Soriano, et al.
Publicado: (2015)

Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes
por: Jungius, Sarah, et al.
Publicado: (2023)

CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results
por: Li, Zhihui, et al.
Publicado: (2023)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review
por: Puckrin, Robert, et al.
Publicado: (2023)

Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation
por: Shumilov, Evgenii, et al.
Publicado: (2021)

Interleukin-10-592 polymorphism: impact on relapse and survival after allogeneic hematopoietic stem cell transplantation in children with hematological malignancies
por: Schwenk, Laura, et al.
Publicado: (2021)

Is It Better to Mobilize Hematopoietic Stem Cells With Pegfilgrastim in Healthy Donors During Allogeneic Hematopoietic Stem Cell Transplantation?
por: Li, Jiali, et al.
Publicado: (2020)

Editorial: Reviews in hematologic malignancies
por: Saraceni, Francesco, et al.
Publicado: (2022)

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases
por: Gerhardt, Kristin, et al.
Publicado: (2021)

Correlative factors of ocular surface lesions after allogeneic hematopoietic stem cell transplantation: A retrospective study
por: Zhuang, Xin-Yu, et al.
Publicado: (2022)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Cardiac Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
por: Facenda-Lorenzo, María, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_smldusvs9l7lcc99mg2sud24ga